[{"id":"118a4b55-36eb-4902-b388-cfb891dcf143","acronym":"","url":"https://clinicaltrials.gov/study/NCT04113122","created_at":"2021-01-18T20:06:31.712Z","updated_at":"2024-07-02T16:35:05.931Z","phase":"","brief_title":"Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study","source_id_and_acronym":"NCT04113122","lead_sponsor":"University Medical Center Groningen","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 02/09/2019","start_date":" 02/09/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-03"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"29615e37-bb63-4054-a44c-541e878490a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05358379","created_at":"2024-02-07T19:21:22.852Z","updated_at":"2024-07-02T16:35:20.542Z","phase":"Phase 1/2","brief_title":"A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma","source_id_and_acronym":"NCT05358379","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" PLK1 • CDKN1A","pipe":" | ","alterations":" MYC expression","tags":["PLK1 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-02-07"},{"id":"fd1666a8-c3ef-43e6-9207-5e19e3282d91","acronym":"NIREC","url":"https://clinicaltrials.gov/study/NCT05289648","created_at":"2022-03-21T19:56:04.999Z","updated_at":"2024-07-02T16:35:21.231Z","phase":"Phase 1","brief_title":"Niraparib in High-grade Endometrial Cancer Trial","source_id_and_acronym":"NCT05289648 - NIREC","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" TP53 • CCND1 • CASP3 • CDKN1A","pipe":" | ","alterations":" CCND1 expression","tags":["TP53 • CCND1 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-02-01"},{"id":"fae39971-a2c0-4146-ae98-d52ecfefd832","acronym":"CHEMOFAST","url":"https://clinicaltrials.gov/study/NCT04247464","created_at":"2021-01-18T20:38:41.351Z","updated_at":"2024-07-02T16:35:34.625Z","phase":"","brief_title":"Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients","source_id_and_acronym":"NCT04247464 - CHEMOFAST","lead_sponsor":"IMDEA Food","biomarkers":" CD8 • CEACAM5 • IL2RA • IL7R • NCAM1 • CD14 • PDK4 • CDKN1A • ISG20","pipe":"","alterations":" ","tags":["CD8 • CEACAM5 • IL2RA • IL7R • NCAM1 • CD14 • PDK4 • CDKN1A • ISG20"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2023-10-05"},{"id":"0785c06c-1bec-445f-b1f6-0f9415e68492","acronym":"","url":"https://clinicaltrials.gov/study/NCT01268579","created_at":"2021-01-18T05:07:46.939Z","updated_at":"2024-07-02T16:35:35.116Z","phase":"","brief_title":"Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma","source_id_and_acronym":"NCT01268579","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • CDKN1A","pipe":"","alterations":" ","tags":["EGFR • CDKN1A"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/28/2010","start_date":" 12/28/2010","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-10-02"},{"id":"fb8dc3ab-b4a9-4b4d-aae6-7233509f61b6","acronym":"Neo Combi","url":"https://clinicaltrials.gov/study/NCT01972347","created_at":"2021-03-01T20:52:35.949Z","updated_at":"2024-07-02T16:35:38.660Z","phase":"Phase 2","brief_title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","source_id_and_acronym":"NCT01972347 - Neo Combi","lead_sponsor":"Melanoma Institute Australia","biomarkers":" EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 05/04/2017","primary_completion_date":" 05/04/2017","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-30"},{"id":"290b7fc0-2551-4b8e-8a40-119d81d3738c","acronym":"VitDURO","url":"https://clinicaltrials.gov/study/NCT04197089","created_at":"2021-01-18T20:27:15.791Z","updated_at":"2024-07-02T16:36:06.166Z","phase":"Phase 4","brief_title":"Biological Effect of Vitamin D in Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04197089 - VitDURO","lead_sponsor":"Germans Trias i Pujol Hospital","biomarkers":" FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5","pipe":"","alterations":" ","tags":["FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/22/2021","study_completion_date":" 11/22/2021","last_update_posted":"2022-08-03"},{"id":"6a14e8e5-6704-4f6d-8d3f-6ec8a3b0b562","acronym":"STARC","url":"https://clinicaltrials.gov/study/NCT02569645","created_at":"2022-06-04T12:54:03.426Z","updated_at":"2024-07-02T16:36:07.105Z","phase":"Phase 2","brief_title":"Rosuvastatin in the Treatment of Rectal Cancer","source_id_and_acronym":"NCT02569645 - STARC","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" RHOA • CDKN1A","pipe":"","alterations":" ","tags":["RHOA • CDKN1A"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2022-07-20"},{"id":"4c36bc05-4f8b-4445-89c4-c81896c29440","acronym":"BioPER","url":"https://clinicaltrials.gov/study/NCT03184090","created_at":"2021-01-18T15:42:02.729Z","updated_at":"2024-07-02T16:36:08.551Z","phase":"Phase 2","brief_title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","source_id_and_acronym":"NCT03184090 - BioPER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 06/28/2017","start_date":" 06/28/2017","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 10/27/2020","study_completion_date":" 10/27/2020","last_update_posted":"2022-06-21"},{"id":"a25a7657-8064-40e7-806c-f6d355167a9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042531","created_at":"2021-09-13T14:55:55.634Z","updated_at":"2024-07-02T16:36:11.575Z","phase":"","brief_title":"Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia","source_id_and_acronym":"NCT05042531","lead_sponsor":"LanZhou University","biomarkers":" TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A","pipe":"","alterations":" ","tags":["TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-04-25"},{"id":"11f21814-8048-4c09-a674-b93785eb65ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02178072","created_at":"2021-01-18T10:09:20.164Z","updated_at":"2024-07-02T16:36:17.134Z","phase":"Phase 1","brief_title":"Window Trial 5-aza in HNSCC, T-tare","source_id_and_acronym":"NCT02178072","lead_sponsor":"Yale University","biomarkers":" CASP3 • CDKN1A","pipe":"","alterations":" ","tags":["CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 02/19/2015","start_date":" 02/19/2015","primary_txt":" Primary completion: 10/23/2019","primary_completion_date":" 10/23/2019","study_txt":" Completion: 10/23/2019","study_completion_date":" 10/23/2019","last_update_posted":"2022-02-15"},{"id":"7cfa6f26-875f-4193-9aef-c545fb2ab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554707","created_at":"2021-01-18T17:29:50.207Z","updated_at":"2024-07-02T16:36:17.444Z","phase":"Phase 1","brief_title":"SGT-53 in Children With Recurrent or Progressive CNS Malignancies","source_id_and_acronym":"NCT03554707","lead_sponsor":"SynerGene Therapeutics, Inc.","biomarkers":" MGMT • MDM2 • CDKN1A","pipe":" | ","alterations":" ATRX mutation • MDM2 mutation","tags":["MGMT • MDM2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • MDM2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-02-08"},{"id":"3b9e996c-b0bb-4715-96ec-d4cf82e70b34","acronym":"","url":"https://clinicaltrials.gov/study/NCT01644994","created_at":"2021-01-18T07:05:09.242Z","updated_at":"2024-07-02T16:36:23.747Z","phase":"Phase 2","brief_title":"Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT01644994","lead_sponsor":"University of Zurich","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-09-29"},{"id":"e95d4d0f-1b25-4707-99e1-e24e935ca1e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00695201","created_at":"2021-01-18T02:35:55.347Z","updated_at":"2024-07-02T16:36:28.423Z","phase":"Phase 1","brief_title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","source_id_and_acronym":"NCT00695201","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 06/28/2021","primary_completion_date":" 06/28/2021","study_txt":" Completion: 06/28/2021","study_completion_date":" 06/28/2021","last_update_posted":"2021-07-01"},{"id":"aca713f2-d513-4eb6-b7b6-18e9f561a9b2","acronym":"SenPET","url":"https://clinicaltrials.gov/study/NCT04536454","created_at":"2021-01-18T21:42:42.193Z","updated_at":"2024-07-02T16:36:30.475Z","phase":"Phase 1/2","brief_title":"Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)","source_id_and_acronym":"NCT04536454 - SenPET","lead_sponsor":"University Hospital Tuebingen","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-05-11"},{"id":"ba13b520-f784-4843-94ad-25ed16f7e5fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01344330","created_at":"2021-01-18T05:29:15.502Z","updated_at":"2024-07-02T16:36:37.142Z","phase":"","brief_title":"Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients","source_id_and_acronym":"NCT01344330","lead_sponsor":"Texas A\u0026M University","biomarkers":" CDKN1A","pipe":"","alterations":" ","tags":["CDKN1A"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2020-12-19"},{"id":"a599bd6d-bb48-4886-a056-1c6c4c34af61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343172","created_at":"2021-01-18T11:08:16.439Z","updated_at":"2024-07-02T16:36:37.589Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma","source_id_and_acronym":"NCT02343172","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDK4 • GDF15 • CDKN1A","pipe":"","alterations":" ","tags":["CDK4 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 03/13/2015","start_date":" 03/13/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/16/2019","study_completion_date":" 10/16/2019","last_update_posted":"2020-12-09"},{"id":"acdd08fa-2d65-43f2-9dc7-c1e5e7171d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00068380","created_at":"2021-01-18T00:10:06.283Z","updated_at":"2024-07-02T16:37:09.032Z","phase":"Phase 2","brief_title":"A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer","source_id_and_acronym":"NCT00068380","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2 • CDKN1A","pipe":" | ","alterations":" CDKN1B expression","tags":["TP53 • BCL2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 03/01/2010","study_completion_date":" 03/01/2010","last_update_posted":"2018-07-11"},{"id":"c124e77c-6bb2-4053-bf1f-8c73601ac88f","acronym":"FOKAL-BT","url":"https://clinicaltrials.gov/study/NCT02391051","created_at":"2021-01-18T11:24:01.627Z","updated_at":"2024-07-02T16:37:18.932Z","phase":"Phase 2","brief_title":"Focal Brachytherapy in Patients With Selected \"Low-risk\" Prostate Cancer - a Phase-II-trial","source_id_and_acronym":"NCT02391051 - FOKAL-BT","lead_sponsor":"University of Erlangen-Nürnberg Medical School","biomarkers":" FGFR1 • CDKN1A • MIR141","pipe":"","alterations":" ","tags":["FGFR1 • CDKN1A • MIR141"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2017-08-11"},{"id":"d694717e-b927-4af3-9e74-7306f9efff05","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188252","created_at":"2021-01-18T04:45:06.986Z","updated_at":"2025-02-25T17:18:29.403Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01188252","lead_sponsor":"Bayer","biomarkers":" CASP3 • CDKN1A • ANXA5","pipe":" | ","alterations":" MCL1 expression","tags":["CASP3 • CDKN1A • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-09"}]